Compare Enveric Biosciences Inc (ENVB) vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 (USOI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $45.28 (market cap $311.72M). The key difference: Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 is far larger — about 45.8× Enveric Biosciences Inc's market cap, and Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 for 48 Days on average.
| ENVB | USOI | |
|---|---|---|
Market Cap | $6.80M | $311.72M |
Volume | 64,867 | 75,888 |
Sector | Health | Income / Options Overlay |
52-Week High | $10.80 | $61.17 |
52-Week Low | $1.27 | $42.27 |
Typical Hold Time | 14 Days | 48 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
USOI trades at $44.61, down 0.82% today, with a bearish technical signal driven by moving averages. Support levels are at $44 and $43, while resistance sits at $45 and $46. Financial ratios like P/E and P/S are unavailable in the data, limiting fundamental clarity. Recent portfolio commentary from Seeking Alpha on September 3, 2026, highlighted strategic cash-raising moves, though direct company news is sparse.
The outlook is cautious due to weak technical momentum and absent fundamental metrics. Risks include market volatility and lack of earnings visibility. Investment opportunity hinges on a rebound above resistance, but current sentiment and technicals suggest near-term pressure for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037
USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →
